We are proud to officially announce that Simon Dabekaussen, former Corporate Development manager at Liberi Group, has been appointed Chief Operating Officer. Liberi Group’s shareholders decided to appoint a candidate with a comprehensive understanding of Liberi Group, its clients, and its markets, combined with a strong relationship with the extensive Pharma and Investors network, who will be able to ensure the continuity of the company’s objectives.
Simon will work alongside CEO and Founder Frans Trouwen, to manage the growth and quality of Liberi Group and will be responsible for the day-to-day operations of the team and supporting our client portfolios. Over the last 2 years, the team of Liberi Group has grown from 5 employees to currently 17 industry professionals. The significant growth within the team is a result of the high market demand to support biotech by finding strategic partners, investment search, in-licensing opportunities, mergers and acquisitions, and other business development models like Pharma divestment and Biotech Valuation. In the coming months, Liberi Group is expected to continue its growth and maintain its quality under the supervision of Simon.